Biotech News

Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026

Enlivex Therapeutics (ENLV)Enlivex TherapeuticsCompany update

Nes-Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company, today announced a 1-for-15 reverse split (the "Reverse Split") of its ordinary shares. Beginning on July 9, 2026, the Company's ordinary shares will trade on The Nasdaq Capital Market on a split-adjusted basis.

As a...

Related news

Enlivex Therapeutics

Enlivex Therapeutics is an immunotherapy company focused on macrophage reprogramming and inflammation-related disease. Its story is centered on harnessing innate immunity to address hard-to-treat conditions.

Recent company news

Stock data

Close
1.47 USD
Market cap
204.87M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States